Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 6/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249321 | 0.99 | MET (0.47) | METTLR9KCNH2HRH3 | |
| SCHEMBL10249337 | 0.94 | EPHX2 (0.43) | METTLR9HRH3 | |
| SCHEMBL10253105 | 0.93 | MET (0.41) | METTLR9 | |
| SCHEMBL10252435 | 0.93 | EPHX2 (0.49) | — | |
| SCHEMBL10097292 | 0.91 | HRH3 (0.46) | METKCNH2HRH3 | |
| SCHEMBL10097289 | 0.90 | HRH3 (0.48) | KCNH2HRH3 | |
| SCHEMBL10097322 | 0.89 | CDC7 (0.46) | — | |
| SCHEMBL10097802 | 0.89 | MET (0.46) | METTLR9TLR7HRH3 | |
| SCHEMBL12334327 | 0.88 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL979546 | 0.88 | MET (0.46) | METTLR9HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | MET 1782/4885TLR9 1524/4885TLR7 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.